Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Vedere Bio II
Headquarters: Cambridge, MA, United States of America
Website: N/A
Year Founded: 2020
Status: Out of Business
BioCentury | Jul 26, 2023
Management Tracks
New CEOs for Catalyst, FibroGen, Pheon and Tae
Plus: Nicole Sweeny named chief commercial officer of KalVista
BioCentury | Apr 4, 2023
Regulation
April 3 Quick Takes: Padcev label expanded to first-line urothelial cancer
Plus: Ascendis’ market cap melts as thyroid program hits FDA snag and updates from Apellis, Vedere and Vertex-CRISPR
BioCentury | May 20, 2022
Discovery & Translation
Optimizing CNS tropism for AAVs at ASGCT
Directed evolution, genetic library screening and peptide modifications were the most common strategies presented
BioCentury | Apr 26, 2022
Management Tracks
Stoffels becomes Galapagos board chairman
Plus Vedere Bio II and management moves at Jnana, Flare, DeepCure and more
BioCentury | Apr 12, 2022
Management Tracks
Consylman now at Vedere Bio II
Plus Neuron23 hires Jackson and updates from Sitryx, Illumina, Alto and more
BioCentury | Jun 22, 2021
Management Tracks
Wigerinck to leave Galapagos; plus Kymera, Alladapt, Nurix, Alchemab, Novome and more
Piet Wigerinck will step down this year after serving as CSO for nine years at Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), overseeing the Belgian biotech’s programs from the discovery of
BioCentury | May 18, 2021
Finance
May 18 Quick Takes: Temasek backs Wilson, Yamada to form G2 Bio; plus PathAI, Interius, Vedere II and more
Singapore-based Temasek will supply $200 million to G2 Management Co. Inc. to foster the development of therapies from the University of Pennsylvania's Gene Therapy Program, led by James Wilson.
BioCentury | Oct 30, 2020
Deals
Via takeout of Atlas-grown optogenetic play for $150M up front, Novartis adds to gene therapy arsenal
Vedere Bio II spins out with vision restoration and preservation programs
Items per page:
1 - 8 of 8